PRG-2302 / Pregene Biotech - LARVOL DELTA

Exploratory clinical study of the safety and efficacy of PRG2302 for the treatment of relapsed or refractory B-cell lymphoma (ChiCTR) - P=N/A | N=18 | Sponsor: The First People’s Hospital of Jingzhou; The First People’s Hospital of Jingzhou

New trial • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • CD4 • CD8 • IL10 • IL2 • IL4 • IL6